Study uncovers how blood cancers evade BTK-targeted therapies

Scientists from Sylvester Comprehensive Cancer Center at the University of Miami have identified a rare mutation that can make certain blood cancers resistant to nearly every Bruton tyrosine kinase (BTK)–targeted therapy, including both approved BTK inhibitors and newer BTK degraders. The work focuses on chronic lymphocytic leukemia (CLL) and related B-cell malignancies, where BTK-targeting drugs have become a cornerstone of care.

The study, published in Cancer Discovery, pinpoints a specific change in the BTK gene—known as BTK A428D—as a potent “pan-resistance” mechanism. Importantly, the authors report that this mutation undermines therapeutic strategies across multiple drug classes that aim to disrupt BTK-dependent signaling.

BTK inhibitors work by binding to the BTK protein, blocking signals that cancer cells rely on for growth and survival. BTK degraders take a different approach: rather than simply blocking BTK activity, they recruit cellular machinery to eliminate the BTK protein. Previous laboratory findings suggested that the most common resistance mutations to inhibitors might remain vulnerable to degraders, setting up an expectation that degraders could broaden durability.

Using molecular, biochemical, and structural analyses, the researchers show that A428D forces the BTK protein into an altered three-dimensional conformation. In that reshaped state, drugs cannot attach effectively, explaining why both inhibitor binding and degrader-based targeting fail. “The surprising part was that the BTK A428D has a completely different conformation that makes it impossible for any drugs to bind to it,” said co-author Justin Taylor, M.D.

The team also describes a biological tradeoff: the mutation reduces cancer-cell fitness. That constraint may help explain why A428D is observed more often in patients treated with BTK degraders than in those receiving inhibitors alone.

Beyond diagnosis of the problem, the study explores prevention. In preclinical models, combining BTK degraders with a different drug class that targets the BCL2 protein prevented the emergence of resistant cancer cells. This supports further testing of combination strategies designed to keep tumors from evolving escape routes.

While A428D accounts for resistance in some patients, not all progressed cases share the mutation, indicating additional mechanisms remain to be discovered. Still, the new structural blueprint offers a roadmap for identifying at-risk patients and designing therapies that can bypass or neutralize resistance.

Overall, the findings highlight a viral-newsworthy message for targeted oncology: cancer evolution can outmaneuver even next-generation drugs, but structural insight may help clinicians stay several steps ahead.